Advertisement

Fractionated stereotactic radiosurgery for malignant gliomas: comparison with single session stereotactic radiosurgery

  • Seung Won Choi
  • Kyung Rae Cho
  • Jung Won Choi
  • Doo-Sik Kong
  • Ho Jun Seol
  • Do-Hyun Nam
  • Jung-Il LeeEmail author
Clinical Study

Abstract

Purpose

Stereotactic radiosurgery (SRS) is feasible for malignant glioma; however, delivering the optimal radiation dose with sufficient large-volume coverage is a major concern. We aimed to investigate the clinical efficacy and safety of fractionated SRS (fSRS) versus single-session SRS (sSRS) for malignant gliomas.

Methods

We retrospectively reviewed 58 malignant glioma patients who underwent gamma knife SRS from January 2015 to December 2018. Forty-one underwent sSRS, and 17 underwent fSRS. Median dose for fSRS was 28 Gy (range 24–35 Gy), with a median dose of 6 Gy per fraction (range 5–7 Gy). Patients received 4 or 5 fractions on consecutive days. Median dose for sSRS was 18 Gy (range 11–25 Gy), with a median isodose of 50% (range 50–65%). Mean target volumes were 5.9 and 19.3 cc for sSRS and fSRS, respectively (p < 0.001, two-sided t test).

Results

After SRS, median progression-free survival (PFS) was 4.5 and 4.6 months (p = 0.58), and median overall survival (OS) was 12.7 and 12.6 months for sSRS and fSRS (p = 0.41), respectively (log-rank test). The incidence of clinically significant radiation necrosis was 20.5% (8/39) and 18.8% (3/16) for sSRS and fSRS, respectively (p = 1, Fisher’s exact test).

Conclusion

fSRS for malignant glioma conferred local control and survival comparable with conventional sSRS. The radiation necrosis incidence was comparable between groups when a parallel biological effective dose was administered to the larger target volumes in the fSRS group. fSRS can be a better alternative to sSRS if re-irradiation is considered for large malignant gliomas.

Keywords

Stereotactic radiosurgery Fractionated stereotactic radiosurgery High-grade glioma 

Notes

Funding

None.

Compliance with ethical standards

Conflict of interest

The authors declare no potential conflict of interest.

References

  1. 1.
    Omuro A, DeAngelis LM (2013) Glioblastoma and other malignant gliomas: a clinical review. JAMA 310:1842–1850.  https://doi.org/10.1001/jama.2013.280319 CrossRefPubMedGoogle Scholar
  2. 2.
    Weller M, Cloughesy T, Perry JR, Wick W (2013) Standards of care for treatment of recurrent glioblastoma–are we there yet? Neuro Oncol 15:4–27.  https://doi.org/10.1093/neuonc/nos273 CrossRefPubMedGoogle Scholar
  3. 3.
    Shah JL, Li G, Shaffer JL, Azoulay MI, Gibbs IC, Nagpal S, Soltys SG (2018) Stereotactic radiosurgery and hypofractionated radiotherapy for glioblastoma. Neurosurgery 82:24–34.  https://doi.org/10.1093/neuros/nyx115 CrossRefPubMedGoogle Scholar
  4. 4.
    Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, Belanger K, Brandes AA, Marosi C, Bogdahn U, Curschmann J, Janzer RC, Ludwin SK, Gorlia T, Allgeier A, Lacombe D, Cairncross JG, Eisenhauer E, Mirimanoff RO, Europe an Organisation for R, Treatment of Cancer Brain T, Radiotherapy G, National Cancer Institute of Canada Clinical Trials G (2005) Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352:987–996.  https://doi.org/10.1056/NEJMoa043330 CrossRefGoogle Scholar
  5. 5.
    Stupp R, Brada M, van den Bent MJ, Tonn JC, Pentheroudakis G, Group EGW (2014) High-grade glioma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 25:93–101CrossRefGoogle Scholar
  6. 6.
    Shaw E, Scott C, Souhami L, Dinapoli R, Kline R, Loeffler J, Farnan N (2000) Single dose radiosurgical treatment of recurrent previously irradiated primary brain tumors and brain metastases: final report of RTOG protocol 90–05. Int J Radiat Oncol Biol Phys 47:291–298.  https://doi.org/10.1016/s0360-3016(99)00507-6 CrossRefPubMedGoogle Scholar
  7. 7.
    Vogelbaum MA, Angelov L, Lee SY, Li L, Barnett GH, Suh JH (2006) Local control of brain metastases by stereotactic radiosurgery in relation to dose to the tumor margin. J Neurosurg 104:907–912.  https://doi.org/10.3171/jns.2006.104.6.907 CrossRefPubMedGoogle Scholar
  8. 8.
    Kirkpatrick JP, Soltys SG, Lo SS, Beal K, Shrieve DC, Brown PD (2017) The radiosurgery fractionation quandary: single fraction or hypofractionation? Neuro Oncol 19:ii38–ii49.  https://doi.org/10.1093/neuonc/now301 CrossRefPubMedPubMedCentralGoogle Scholar
  9. 9.
    Louis DN, Perry A, Reifenberger G, von Deimling A, Figarella-Branger D, Cavenee WK, Ohgaki H, Wiestler OD, Kleihues P, Ellison DW (2016) The 2016 World Health Organization classification of tumors of the central nervous system: a summary. Acta Neuropathol 131:803–820.  https://doi.org/10.1007/s00401-016-1545-1 CrossRefGoogle Scholar
  10. 10.
    Kong DS, Lee JI, Park K, Kim JH, Lim DH, Nam DH (2008) Efficacy of stereotactic radiosurgery as a salvage treatment for recurrent malignant gliomas. Cancer 112:2046–2051.  https://doi.org/10.1002/cncr.23402 CrossRefPubMedGoogle Scholar
  11. 11.
    Lee MH, Kim KH, Cho KR, Choi JW, Kong DS, Seol HJ, Nam DH, Lee JI (2019) Volumetric changes of intracranial metastases during the course of fractionated stereotactic radiosurgery and significance of adaptive planning. J Neurosurg 1:1–6.  https://doi.org/10.3171/2019.3.JNS183130 CrossRefGoogle Scholar
  12. 12.
    Wen PY, Macdonald DR, Reardon DA, Cloughesy TF, Sorensen AG, Galanis E, Degroot J, Wick W, Gilbert MR, Lassman AB, Tsien C, Mikkelsen T, Wong ET, Chamberlain MC, Stupp R, Lamborn KR, Vogelbaum MA, van den Bent MJ, Chang SM (2010) Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group. J Clin Oncol 28:1963–1972.  https://doi.org/10.1200/JCO.2009.26.3541 CrossRefPubMedGoogle Scholar
  13. 13.
    Hochberg FH, Pruitt A (1980) Assumptions in the radiotherapy of glioblastoma. Neurology 30:907–911.  https://doi.org/10.1212/wnl.30.9.907 CrossRefPubMedGoogle Scholar
  14. 14.
    Wallner KE, Galicich JH, Krol G, Arbit E, Malkin MG (1989) Patterns of failure following treatment for glioblastoma multiforme and anaplastic astrocytoma. Int J Radiat Oncol Biol Phys 16:1405–1409.  https://doi.org/10.1016/0360-3016(89)90941-3 CrossRefPubMedGoogle Scholar
  15. 15.
    R Core Team (2014) R: a language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria. https://www.R-project.org/. Accessed 26 June 2019
  16. 16.
    Niranjan A, Kano H, Iyer A, Kondziolka D, Flickinger JC, Lunsford LD (2015) Role of adjuvant or salvage radiosurgery in the management of unresected residual or progressive glioblastoma multiforme in the pre-bevacizumab era. J Neurosurg 122:757–765.  https://doi.org/10.3171/2014.11.JNS13295 CrossRefPubMedGoogle Scholar
  17. 17.
    Imber BS, Kanungo I, Braunstein S, Barani IJ, Fogh SE, Nakamura JL, Berger MS, Chang EF, Molinaro AM, Cabrera JR, McDermott MW, Sneed PK, Aghi MK (2017) Indications and efficacy of gamma knife stereotactic radiosurgery for recurrent glioblastoma: 2 decades of institutional experience. Neurosurgery 80:129–139.  https://doi.org/10.1227/NEU.0000000000001344 CrossRefPubMedGoogle Scholar
  18. 18.
    Sharma M, Schroeder JL, Elson P, Meola A, Barnett GH, Vogelbaum MA, Suh JH, Chao ST, Mohammadi AM, Stevens GHJ, Murphy ES, Angelov L (2018) Outcomes and prognostic stratification of patients with recurrent glioblastoma treated with salvage stereotactic radiosurgery. J Neurosurg.  https://doi.org/10.3171/2018.4.JNS172909 CrossRefPubMedGoogle Scholar
  19. 19.
    Greenspoon JN, Sharieff W, Hirte H, Overholt A, Devillers R, Gunnarsson T, Whitton A (2014) Fractionated stereotactic radiosurgery with concurrent temozolomide chemotherapy for locally recurrent glioblastoma multiforme: a prospective cohort study. Onco Targets Ther 7:485–490.  https://doi.org/10.2147/OTT.S60358 CrossRefPubMedPubMedCentralGoogle Scholar
  20. 20.
    Hudes RS, Corn BW, Werner-Wasik M, Andrews D, Rosenstock J, Thoron L, Downes B, Curran WJ Jr (1999) A phase I dose escalation study of hypofractionated stereotactic radiotherapy as salvage therapy for persistent or recurrent malignant glioma. Int J Radiat Oncol Biol Phys 43:293–298.  https://doi.org/10.1016/s0360-3016(98)00416-7 CrossRefPubMedGoogle Scholar
  21. 21.
    Dale RG (1985) The application of the linear-quadratic dose-effect equation to fractionated and protracted radiotherapy. Br J Radiol 58:515–528.  https://doi.org/10.1259/0007-1285-58-690-515 CrossRefPubMedGoogle Scholar
  22. 22.
    Bentzen SM, Dorr W, Gahbauer R, Howell RW, Joiner MC, Jones B, Jones DT, van der Kogel AJ, Wambersie A, Whitmore G (2012) Bioeffect modeling and equieffective dose concepts in radiation oncology–terminology, quantities and units. Radiother Oncol 105:266–268.  https://doi.org/10.1016/j.radonc.2012.10.006 CrossRefPubMedGoogle Scholar
  23. 23.
    Ene CI, Macomber MW, Barber JK, Ferreira MJ, Ellenbogen RG, Holland EC, Rockhill JK, Silbergeld DL, Halasz LM (2019) Patterns of failure after stereotactic radiosurgery for recurrent high-grade glioma: a single institution experience of 10 years. Neurosurgery 85:E322–E331.  https://doi.org/10.1093/neuros/nyy520 CrossRefPubMedGoogle Scholar
  24. 24.
    Brandes AA, Tosoni A, Franceschi E, Sotti G, Frezza G, Amista P, Morandi L, Spagnolli F, Ermani M (2009) Recurrence pattern after temozolomide concomitant with and adjuvant to radiotherapy in newly diagnosed patients with glioblastoma: correlation With MGMT promoter methylation status. J Clin Oncol 27:1275–1279.  https://doi.org/10.1200/JCO.2008.19.4969 CrossRefPubMedGoogle Scholar
  25. 25.
    Cuneo KC, Vredenburgh JJ, Sampson JH, Reardon DA, Desjardins A, Peters KB, Friedman HS, Willett CG, Kirkpatrick JP (2012) Safety and efficacy of stereotactic radiosurgery and adjuvant bevacizumab in patients with recurrent malignant gliomas. Int J Radiat Oncol Biol Phys 82:2018–2024.  https://doi.org/10.1016/j.ijrobp.2010.12.074 CrossRefPubMedGoogle Scholar
  26. 26.
    Frischer JM, Marosi C, Woehrer A, Hainfellner JA, Dieckmann KU, Eiter H, Wang WT, Mallouhi A, Ertl A, Knosp E, Filipits M, Kitz K, Gatterbauer B (2016) Gamma knife radiosurgery in recurrent glioblastoma. Stereotact Funct Neurosurg 94:265–272.  https://doi.org/10.1159/000448924 CrossRefPubMedGoogle Scholar
  27. 27.
    Gigliotti MJ, Hasan S, Karlovits SM, Ranjan T, Wegner RE (2018) Re-irradiation with stereotactic radiosurgery/radiotherapy for recurrent high-grade gliomas: improved survival in the modern era. Stereotact Funct Neurosurg 96:289–295.  https://doi.org/10.1159/000493545 CrossRefPubMedGoogle Scholar
  28. 28.
    Fetcko K, Lukas RV, Watson GA, Zhang L, Dey M (2017) Survival and complications of stereotactic radiosurgery: a systematic review of stereotactic radiosurgery for newly diagnosed and recurrent high-grade gliomas. Medicine (Baltimore) 96:e8293.  https://doi.org/10.1097/MD.0000000000008293 CrossRefGoogle Scholar
  29. 29.
    Cho KH, Hall WA, Gerbi BJ, Higgins PD, McGuire WA, Clark HB (1999) Single dose versus fractionated stereotactic radiotherapy for recurrent high-grade gliomas. Int J Radiat Oncol Biol Phys 45:1133–1141.  https://doi.org/10.1016/s0360-3016(99)00336-3 CrossRefPubMedGoogle Scholar
  30. 30.
    Pinzi V, Orsi C, Marchetti M, Milanesi IM, Bianchi LC, DiMeco F, Cuccarini V, Farinotti M, Ferroli P, Finocchiaro G, Franzini A, Fumagalli M, Silvani A, Fariselli L (2015) Radiosurgery reirradiation for high-grade glioma recurrence: a retrospective analysis. Neurol Sci 36:1431–1440.  https://doi.org/10.1007/s10072-015-2172-7 CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2019

Authors and Affiliations

  1. 1.Department of NeurosurgerySungkyunkwan University School of Medicine, Samsung Medical CenterSeoulRepublic of Korea

Personalised recommendations